S. Schneider

Gefitinib (IressaTM, ZD1839) and Tyrosine Kinase Inhibitors: The Wave of the Future in Cancer Therapy

K. Penne, C. Bohlin, S. Schneider, 2005, Cancer nursing.

Improvement of breast cancer prognostication using cell kinetic-based silver-stainable nucleolar organizer region quantification of the MIB-1 positive tumor cell compartment

P. Hufnagl, F. Farokhzad, S. Biesterfeld, 2001, Virchows Archiv.

Letrozole and Fulvestrant Combination in Second Line or More for Estrogen Receptor Positive Metastatic Breast Cancer; Efficacy and Predictive Factors of Response

M. Bolton, S. Schneider, M. Copur, 2011 .

Estrogen and androgen dynamics in liver disease

C. Longcope, E. Fineberg, J. Pratt, 1984, Journal of endocrinological investigation.

Comparison of cytosol estrogen receptor status in ovarian carcinoma using different radiolabeled ligands and methods

M. Piver, S. Lele, J. Barlow, 1982, Journal of surgical oncology.

Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow‐up study on breast cancer using antibodies against MIB‐1, PCNA, ER, and PR

S. Biesterfeld, W. Schröder, S. Schneider, 1998, The Journal of pathology.

Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer.

K. Friedrich, M. Wirth, W. Meyer, 2010, Analytical and quantitative cytology and histology.